Attenuated Bacteria-Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping...

Area of Science:

• Oncology
• Microbiology
• Biotechnology

Background:

• Bacteria-based cancer therapy is an emerging strategy using engineered bacteria to target and eliminate cancer cells or stimulate immune responses.
• Clinical trials are underway, but significant hurdles impede the translation of this therapy into widespread clinical use.

Purpose of the Study:

• To review the critical challenges and advancements in bacteria-based cancer therapy.
• To explore strategies for improving safety, efficacy, monitoring, production, and regulatory pathways for clinical translation.

Main Methods:

• Summarizing safety risks and bacterial attenuation strategies.
• Discussing methods for regulating therapeutic stability and optimizing production processes.
• Reviewing in vivo imaging technologies and market approval pathways.

Main Results:

• Identified key challenges including safety, efficacy fluctuations, in vivo monitoring difficulties, quality control, and regulatory standards.
• Highlighted the potential of genetic circuits for precise control of bacterial behavior.
• Emphasized the role of multimodal imaging for real-time treatment monitoring.

Conclusions:

• Precise control of bacterial behavior and real-time monitoring are crucial for successful clinical translation.
• Addressing safety, efficacy, and regulatory issues is essential for advancing bacteria-based cancer therapies.
• This review provides a framework for overcoming obstacles and promoting the clinical application of engineered bacteria in cancer treatment.